Press releaseGlobe Newswire
Phathom Pharmaceuticals
PHAT · NASDAQ
$7.31+$0.30 (+4.28%)TodayMarket closed ·
Prev close $7.01
Latest news
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
- Press releaseBusiness Wire
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
- Press releasePRNewswire
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals
- Press releasePRNewswire
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)
- News
Phathom Pharmaceuticals Q2 Adj. EPS $0.00 Beats $(0.25) Estimate, Sales $74.300M Beat $72.789M Estimate
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
- News
Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
- News
Earnings Scheduled For April 30, 2026
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
- News
Phathom Pharmaceuticals Earnings Review: Q4 Summary
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
- News
Earnings Scheduled For February 26, 2026
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
- NewsVandana Singh
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability
- NewsRishabh Mishra
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
- NewsVaishali Prayag
Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Palo Alto Networks, Take-Two Interactive Software, VF Corp And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
- News
Insights Ahead: Phathom Pharmaceuticals's Quarterly Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.